Search results
How 1301B7 Could Contribute To Advanced Vaccine Development
Forbes· 19 hours agoIn the ongoing Omicron era, a new COVID-19 antibody could renew optimism for urgently required...
Flu Breakthrough: Vanderbilt Scientists Discover Powerful New Weapon
SciTechDaily· 2 days agoVanderbilt University researchers have identified potent monoclonal antibodies against influenza B, showcasing a promising avenue for treatment and preventative strategies in combating the virus ...
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Medscape· 4 days agoThe Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug...
Fauci Testimony Turns Chaotic: 'Most Insane Hearing I've Attended'
Rolling Stone· 4 days agoA hearing in the House Oversight Committee once again devolved into chaos as Republican lawmakers...
...Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with...
KOIN News 6 Portland· 5 days ago...that develops, manufactures and commercializes high-quality medicines for the treatment of...
Humans May Be Able to Grow New Teeth Within Just 6 Years
Popular Mechanics via Yahoo News· 4 days agoBack in 2021, scientists from the Kyoto University—who will also be involved in future human...
Annexon shares leap as Guillain-Barré drug reduces disability in phase 3
FierceBiotech· 3 days agoAnnexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune...
FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety
FierceBiotech· 1 day agoThe docs for Eli Lilly’s donanemab advisory committee meeting are in: the FDA has raised concerns...
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Pharmaceutical Technology via Yahoo Finance· 5 days agoCStone's sugemalimab has been recommended in combination with chemotherapy as a first-line treatment...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoSugemalimab is expected to become the first anti-PD-L1 monoclonal antibody (mAb) in the world approved in Europe for both first-line squamous and non-squamous ...